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Bone metastases are common, cause significant morbidity and impact on healthcare resources. 
While radiographs, computed tomography (CT), magnetic resonance imaging (MRI) and bone 
scintigraphy have frequently been used for staging the skeleton, it is recognized that these methods 
are insensitive and non-specific for monitoring treatment response in a clinically relevant time 
frame.  
We summarize several recent reports on new functional and hybrid imaging methods including 
single photon emission CT / CT, positron emission tomography / CT and whole-body MRI with 
diffusion-weighted imaging. 
These modalities generally show improvements in diagnostic accuracy for staging and response 
assessment over standard imaging methods, with the ability to quantify biological processes related 
to the bone microenvironment as well as tumor cells. 
As some of these methods are now being adopted into routine clinical practice and clinical trials, 
further evaluation with comparative studies are still required to guide optimal and cost effective 
clinical management of patients with skeletal metastases. 
 
Introduction: 
Bone metastases are common, particularly in patients with two of the commonest cancers, breast 
and prostate cancer, where up to 70% of patients are affected.(1) Skeletal-related events secondary 
to bone metastases from any cancer are associated with significant morbidity such as pain, 
hypercalcemia, fractures, bone marrow suppression and spinal cord compression.(2) With more 
effective, but more costly, therapeutics for metastatic breast and prostate cancer, survival is 
relatively long compared to other cancers, and so health care costs are high.(3,4) It is therefore not 
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only important to diagnose skeletal metastases as early as possible but to determine which patients 
are not responding to therapy. An early transition to second-line therapy can then be considered 
with the aims of reducing toxicity from ineffective treatment and to increase quality of life, 
progression-free and overall survival. 
There is increasing use of biochemical markers of bone turnover and tumor-derived markers in the 
diagnosis and monitoring of skeletal metastases but these are less able to determine overall skeletal 
burden than imaging methods and are unable to localize sites of disease or predict complications.(1) 
Nevertheless, these biomarkers probably have a complementary role to imaging in managing 
patients with skeletal metastases.  
While bone scintigraphy has traditionally been used for detecting skeletal metastases and 
monitoring therapy, it is recognized that sensitivity and specificity are limited, both in detection and 
for monitoring treatment response. Conventional imaging, e.g. radiographs, computed tomography 
(CT) or magnetic resonance imaging (MRI), that relies on size-based criteria for assessing treatment 
response, e.g. Response Evaluation Criteria in Solid Tumors (RECIST),(5) is also limited as bone disease 
is usually considered non-measurable unless associated with a measurable soft tissue component. 
Attempts have been made to incorporate bone scintigraphy with other imaging in breast cancer(6) 
and prostate cancer(7) to improve response assessment but early assessment within a clinically 
relevant time frame remains problematic in clinical practice. 
The combination of either tumor or bone-specific radiotracers with CT or MRI in hybrid scanners, 
e.g. single photon emission computed tomography (SPECT/CT), positron emission tomography /CT 
(PET/CT) or PET/MRI, have potential to improve diagnosis and response assessment with synergy 
between morphological and molecular information. However, despite the potential for gathering 
multiparametric information from metastases that reports on diverse underlying biological and 
morphological tumor characteristics, there have been relatively few reports that have successfully 
exploited these potential benefits. 
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The purpose of this review is to update on the current status of functional and hybrid imaging, 
particularly PET and functional MRI methods, in detection and therapy response monitoring of bone 
metastases with discussion of some potential future methods that show promise (Table 1). 
 
Pathophysiology relevant to imaging: 
Paget’s proposal that metastases are a result of interaction between the seeds (cancer cells) and soil 
(organ microenvironment) is relevant to skeletal metastases and imaging.(8,9) Tumor-specific imaging 
agents may be able to detect metastatic disease at an early stage while within the bone marrow 
(soil) compared to bone-specific imaging methods that require a subsequent change in the bone 
itself. Therefore, bone marrow, e.g. MRI, or tumor-specific, e.g. diffusion-weighted-MRI (DW-MRI) or 
18F-fluorodeoxyglucose (18F-FDG) PET, imaging may detect skeletal metastases before imaging 
methods that rely on changes in mineralized bone tissue (e.g. radiographs, CT, bone scintigraphy, 
18F-fluoride PET). 
Morphologic characteristics of untreated bone metastases vary on a spectrum between lysis 
(osteolytic) and sclerosis (osteoblastic) and reflect different underlying biological mechanisms. While 
lytic metastases are more common and typically occur in lung and breast cancer, sclerotic 
metastases are usually seen in prostate cancer. While either osteolytic or osteoblastic processes may 
predominate in a particular metastasis or tumor type, there is usually a mixture of both processes to 
some extent. 
In the commoner type of metastasis that is predominantly osteolytic, factors such as parathyroid 
hormone related protein (PTHrP), derived from the cancer cells, stimulate osteoblast production of 
receptor activator of nuclear factor-B ligand (RANKL) that in turn stimulates osteoclast maturation 
and activity.(10) The increased osteoclast activity leads to increased local bone resorption at a greater 
rate than attempts at osteoblastic bone formation and repair, with net loss of bone. With the 
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subsequent release of growth factors, such as TGF-,  from the bone matrix there is further 
stimulation of PTHrP and hence a resultant vicious cycle of bone destruction. In metastases where 
osteoblastic processes predominate, a number of tumor-derived growth factors (e.g. platelet-
derived growth factor) contribute to this phenotype by stimulating osteoblasts. It is recognized that 
there is increased osteoblastic activity in lytic metastases and osteoclastic activity in metastases that 
are predominantly sclerotic.(11) During healing following successful treatment, both lytic and sclerotic 
metastases become more sclerotic and osteoblastic bone formation and repair occurs.(12,13) 
Functional and molecular imaging agents that can be used for detection of skeletal metastases can 
be broadly divided into bone-specific and tumor specific agents. Traditionally, most use has been 
made of bone-specific agents such as 99m-Technetium labelled methylene diphosphonate as a 
SPECT tracer (bone scan) and 18F-fluoride as a PET tracer. These agents have similar uptake 
mechanisms and depend to some extent on local blood flow but mainly on osteoblastic 
mineralization activity whereby the labelled molecule is incorporated into mineralizing bone.(14) 
Despite these agents showing higher accumulation in osteoblastic metastases, they are sensitive 
methods for detection and staging in most cancers that are predominantly osteolytic, such as lung 
and breast cancer but relatively insensitive in purely osteolytic disease such as myeloma.(15,16) A 
disadvantage of these imaging agents is that they cannot differentiate osteoblastic activity due to 
tumor progression and growth from that which occurs following successful therapy. As such, an 
increase in activity, or indeed the appearance of new previously inconspicuous lesions, can be seen 
at metastatic sites for several weeks, the so called flare phenomenon.(17-19) An area of academic 
interest that has not yet reached the clinic is the imaging of the osteoclast activity associated with 
skeletal metastases. There has been interest in radiolabeling osteocalcin to exploit the receptors for 
this peptide on osteoclasts.(20) More recently, there has been interest in radiolabeled compounds 
which contain the asparginine-glycine-aspartate (RGD) motif that binds strongly to integrins such as 
v. Osteoclasts express more v integrin than any other cell, adhering to bone matrix via this 
integrin during bone resorption.(21) Preclinical experiments in osteolytic metastatic and PTHrP-
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induced calvarial models have demonstrated osteoclast-specific accumulation.(22,23) In man, 
radiolabeled RGD compounds have shown accumulation in bone metastases from lung cancer and 
also prostate cancer.(24, 25) In the latter report an inverse correlation was seen between lesion uptake 
and CT density in keeping with an osteoclastic mechanism of uptake. A reduction in activity was also 
noted in patients who responded to systemic treatment with abiraterone compared to those who 
had progressive disease. 
Tumor-specific imaging methods rely on different underlying cellular biological characteristics of 
tumors for contrast in the image. Conventional MRI (T1, T2, STIR) detects differences in proton 
density (water content) in tumors compared to normal bone marrow, while the signal from 
diffusion-weighted MRI relates to the restriction of water molecule motion and can be quantified by 
measurement of the apparent diffusion coefficient (ADC).(26,27) Highly cellular tumors show greater  
restriction of water molecule motion than normal bone marrow. Examples of PET tumor-specific 
tracers that show uptake in skeletal metastases include 18F-FDG (cellular glycolysis), 18F-choline 
(cellular choline kinase activity and membrane turnover) and 68Ga-prostate-specific membrane 
antigen (68Ga-PSMA) (cellular PSMA expression in prostate and some other cancers).(28-30) 
 
X-ray based imaging methods: 
Radiographs and CT demonstrate the morphologic consequences of metastases that change the 
density of bone secondary to local changes in mineralization, i.e. as a result of osteolytic or 
osteoblastic activity. The poor sensitivity of radiographs, requiring up to 50% of bone to be 
destroyed before lytic metastases are visible,(31) and slow or absent changes following successful 
therapy, are well-recognized.(32) Similar to bone scintigraphy, CT can show an osteoblastic flare in 
healing metastases following successful treatment, either by showing an increase in density and 




Bone scintigraphy including SPECT and SPECT/CT: 
For several decades bone scintigraphy has been the standard method for staging the skeleton in 
most cancers and for monitoring treatment response, although it is now accepted that there are 
limitations in specificity and sensitivity in detecting disease and in specificity in monitoring treatment 
response.(32,33) The addition of tomographic scan acquisitions (SPECT) followed by the availability of 
hybrid SPECT/CT gamma cameras, has helped improve both sensitivity and specificity in diagnosing 
skeletal metastases.(34-36) The greatest improvement has been in specificity, where the CT 
component of the scan has allowed each scintigraphic hot spot to be more accurately categorized as 
benign or malignant by including the morphologic appearances, leading to an increase in confidence 
in reporting scans with fewer equivocal studies.(36) An increase in sensitivity is also reported, 
resulting from the increased contrast resolution available with SPECT compared to standard planar 
imaging (Fig. 1). 
As discussed above, a disadvantage of bone scintigraphy is an ability to differentiate an increase in 
uptake (or new lesions) due to the flare phenomenon from progressive disease for several weeks or 
months following commencement of new systemic endocrine or chemotherapy.(17-19) If a flare is 
recognized, then this is a favorable prognostic sign.(19) The flare can also be used to improve 
diagnostic accuracy. For example, in high-risk prostate cancer patients at initial staging, if bone 
scintigraphy is repeated 6 weeks after commencing endocrine treatment, a flare occurred in 9/22 
(41%) patients with unequivocal bone metastases, 4/36 (11%) of negative scans became positive for 
bone metastases and a flare occurred in 8/41 equivocal baseline scans, a sign that was 100% 
specific.(37)  
The addition of SPECT or SPECT/CT probably does not improve the performance of bone scintigraphy 
for response evaluation in clinical practice or as an end point in clinical trials. Nevertheless, it is 
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accepted that SPECT and SPECT/CT show additional benefit in staging the skeleton compared to 
planar bone scintigraphy alone. 
 
PET and PET/CT: 
18F-fluoride 
18F-fluoride is a bone-specific PET tracer that was first described in 1962 before the more ubiquitous 
use of 99mTc-labeled diphosphonate agents for imaging with gamma cameras.(38) Uptake depends 
on local blood flow and active mineralization where the fluoride ions replace hydroxyl ions in 
hydroxyapatite to form fluoroapatite in bone mineral. Skeletal uptake, with near 100% first pass 
extraction by bone and background clearance by renal excretion, is more rapid than with 99mTc-
labeled bone agents and so images can be acquired within 60 minutes of injection. These properties, 
combined with the superior spatial and contrast resolution of PET compared to gamma camera 
scintigraphy and SPECT, allow high quality functional images of the skeleton (Fig. 2).(14)  
Absolute quantification is possible with PET and so there has been interest in quantitative imaging of 
the skeleton with the ability to estimate lesional or regional blood flow, mineralization activity 
(plasma clearance of 18F-fluoride to the bone mineral compartment), as well as other physiological 
parameters.(14,16) Good correlations have been shown with skeletal histomorphometry, allowing a 
non-invasive measurement of regional skeletal metabolism.(39, 40) Most of the published literature on 
quantitative 18F-fluoride PET kinetics has concentrated on benign skeletal disease but some work 
exists on using kinetic 18F-fluoride PET parameters to monitor treatment response in skeletal 
metastases.(41-43) The disadvantages of quantitative PET for measuring kinetic parameters is that only 
a relatively small part of the skeleton can be included (~10-20cm Z axis) and a dynamic scan of 
approximately 60 minutes, as well as arterial blood sampling, are required. However, methods have 
been introduced to simplify this methodology to obtain non-invasive arterial input functions from 
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image or population data and to estimate kinetic parameters from static scans of the whole 
skeleton.(44-46)  
Despite the quantitative advantages of PET, most of the published literature describing either 
staging or response assessment of skeletal metastases has been qualitative or semi-quantitative. 
However, 18F-fluoride PET and PET/CT studies in breast, prostate, lung and other cancers have 
shown improved diagnostic accuracy compared to bone scintigraphy +/- SPECT or CT.(47-53) The 
impact of 18F-fluoride PET/CT on the management of patients with cancers other than prostate 
cancer was assessed in a National Oncology PET Registry (NOPR) trial that included 1814 patients 
(781 breast, 380 lung and 653 other cancers).(54) For suspected first osseous metastasis, 18F-fluoride 
PET/CT led to management changes in 24%, 36% and 31% of patients with breast, lung and other 
cancers, respectively. In patients with suspected progressive osseous disease, management changed 
in 60% of breast cancer and 52% of other cancers (lung cancer not recorded). In a similar study of 
3531 patients with prostate cancer (1024 initial staging, 1997 first osseous metastasis, 510 
progressive osseous disease), change in management from non-treatment to treatment occurred in 
47%, 44% and 52%, respectively.(55)  
Measurement of total skeletal metastatic burden is possible with 18F-fluoride PET as there is 
generally high contrast between metastases and normal bone. In prostate cancer, a number of 
studies have shown that global quantitative metrics can predict treatment response and 
progression-free survival or overall survival.(56, 57)  
There are fewer published data on the use of 18F-fluoride PET/CT to monitor treatment response in 
skeletal metastases. Early studies have shown potential utility in monitoring early treatment 
response at 12 weeks to 223Ra-radium chloride(580) and dasatinib.(42) With respect to 223Ra-radium 
chloride treatment in metastatic prostate cancer, 18F-fluoride PET can predict absorbed dose to 
metastases(59) and risk of bone marrow toxicity.(60) In another NOPR study of 2217 patients 
evaluating the efficacy of using 18F-fluoride PET/CT to monitor treatment response, predominantly 
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with prostate (68%), breast (17%) and lung cancer (6%), an overall change in management was 
found in 40%.(61) In breast cancer patients on endocrine treatment, 18F-fluoride PET/CT may show 
heterogeneity of response within and between patients, an observation that can be partly explained 
by the flare phenomenon.(62)  
 
18F-Fluorodeoxyglucose (18F-FDG) 
18F-FDG is regarded as a tumor-specific PET tracer relying on the Warburg effect of increased 
glucose transporters and glycolysis by hexokinase II in most malignant tumors for contrast between 
tumor and normal cells.(63) Interestingly, different skeletal metastatic phenotypes appear to show 
different avidity to 18F-FDG. Osteoblastic metastases characteristically show low or absent uptake 
whereas osteolytic lesions tend to be more 18F-FDG-avid and to be associated with a worse 
prognosis.(64-66) This phenomenon is most recognized in breast cancer and the low avidity of sclerotic 
metastases seems to occur both in treated and untreated disease, especially in the lobular cancer 
subtype.(67) In previously treated disease, despite 18F-FDG-negative appearances due to non-viable 
tumor cells, increased osteoblastic activity demonstrated by increased activity on bone scintigraphy 
or 18F-fluoride PET, may persist much longer.(680) Prostate cancer, typically associated with 
osteoblastic metastases, also tends to show low 18F-FDG avidity in bone and soft tissue metastases, 
and so other PET tracers are used in preference for detecting metastatic disease (see below).  
In most cancers osteolytic disease predominates and there are several reports, including meta-
analyses, of 18F-FDG PET/CT showing greater diagnostic accuracy than bone scintigraphy in most 
cancers, but particularly in breast cancer.(64, 69-72)  
A weakness of conventional imaging is an inability to accurately measure early treatment response 
or non-response, an area where it is hoped that functional imaging can improve clinical practice. It is 
in this area that there is accumulating evidence that 18F-FDG PET/CT is clinically useful and has 
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entered routine practice in some institutions. Taking advantage of the metabolic information to 
interpret the morphologic changes is possible with combined PET/CT and increases specificity. It has 
been reported that progressive breast cancer bone metastases become more lytic and 18F-FDG-avid 
but increased sclerosis can be associated with response and progression.(73, 74) While reduction in 
18F-FDG uptake in metastases (as measured by the maximum standardized uptake value - SUVmax) 
and increased sclerosis on CT has been reported to predict time to progression, only SUVmax 
remained significant in a multivariate model.(75) Additional studies have shown associations between 
changes in 18F-FDG uptake and tumor markers, circulating tumor cells, time to progression and 
skeletal-related events, following systemic endocrine and chemotherapeutic regimes (Fig 3.).(76-79) 
Unlike 18F-fluoride PET or bone scintigraphy, metabolic flare is not a commonly recognized 
phenomenon in 18F-FDG PET imaging of skeletal metastases and does not commonly cause 
difficulties in differentiating progressive disease from post therapy healing in clinical practice. 
However, a flare has been reported in a small number of patients with lung cancer treated with the 
antiangiogenic agent bevacizumab in combination with standard chemotherapy.(80) If there is 
discordant response between metastases in an individual patient this probably reflects true inter-
metastatic heterogeneity of response, an increasingly recognized phenomenon resulting from 
polyclonal differentiation of cancer.(62,81)  
 
Other PET tracers 
The high prevalence of bone metastases, combined with the low uptake of the most commonly used 
PET tracer 18F-FDG, in prostate cancer has led to alternative tracers being used in this cancer. The 
osteoblastic nature of prostate cancer bone metastases means that 18F-fluoride PET is very sensitive 
and, when combined with CT, quite specific in detecting skeletal disease. However, with the 
potential problems with the flare phenomenon and relatively little published data, the use in 
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monitoring treatment response is currently limited, despite promising results from the NOPR 
study.(61)  
There has therefore been interest in a number of tumor-specific tracers relating to tumor 
metabolism and antigen expression. Choline, labelled either with 11C-carbon or 18F-fluorine, has 
become a standard clinical tracer for staging high-risk prostate cancer and patients with biochemical 
recurrence. Uptake is seen in osteoblastic metastases, with even higher activity noted in the rarer 
osteolytic phenotype.(82) In patients treated with hormones, the most sclerotic lesions on CT were 
noted to be choline-negative despite continued 18F-fluoride activity, an observation interpreted as 
showing lack of tumor cell viability post treatment but with continued osteoblastic healing.(83)  
At initial staging of high-risk prostate cancer, choline PET/CT has shown higher accuracy than bone 
scintigraphy in a number of studies(84-86) with similar results in those with biochemical recurrence.(87) 
In a further study that compared 18F-choline and 18F-fluoride PET/CT in patients with prostate 
cancer, some patients showed metastases with 18F-choline but not 18F-fluoride (interpreted as 
showing small volume bone marrow deposits before sufficient osteoblastic activity to be visible with 
18F-fluoride) and vice-versa.(88) As yet, there are no strong prospective data to support the use of 
choline PET/CT in monitoring treatment response. Changes in 11C-choline uptake after docetaxel 
chemotherapy were reported as valuable in identifying patients with progressive disease in spite of 
apparent PSA response.(89) In monitoring response to novel endocrine therapies, results are 
conflicting. One study evaluating enzalutamide response has reported that baseline SUVmax of 18F-
choline PET predicted survival(90) and another described no additional value over measurement of 
PSA alone.(91) In contrast, early imaging at 3 and 6 weeks is predictive of outcome better than PSA 
response in castrate resistant disease treated with abiraterone.(92)  
68Ga-PSMA tracers have been a more recent introduction to clinical practice with advantages in 
sensitivity, specificity and tumor to background contrast (particularly in the skeleton) in comparison 
to 18F-choline PET/CT (Fig. 4).(93) While the level of evidence currently remains low, 68Ga-PSMA is 
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superior to bone scintigraphy in primary staging, while evidence in biochemical recurrence is still 
awaited.(94-96) The superior sensitivity of PSMA-based imaging reflects the high expression of this 
antigen in prostate cancer cells as it is a folate hydrolase that is implicated in cellular folate uptake 
and proliferation.(97) 
 
Magnetic resonance imaging: 
While conventional spin-echo based MRI sequences return poor signal from mineralized bone, they 
will demonstrate bone marrow and are sensitive to tumor within bone marrow and may therefore 
detect metastases before significant bone destruction or sclerosis has occurred.(98) The sensitivity of 
conventional MRI has been increased with the development and clinical integration of new MRI 
sequences. These include spin echo T2-weighted(99) or gradient echo T1-weighted sequences with 
Dixon fat suppression, which produces fat-dominant and water-dominant images, and allow a 
skeletal fat-fraction to be measured(100) and by diffusion weighted sequences, assessing proton 
diffusion, which produces images with increasing b-weighting and allows the apparent diffusion co-
efficient (ADC) to be measured.(101)  Metastases appear of lower signal on fat-dominant images and 
of higher signal on water-dominant images. Metastases typically appear of higher signal on 
increasing b-value diffusion sequences and of higher ADC than the normal bone marrow related to 
the difference in cell size and distribution compared to normal fat cells.  
 
Whole body MRI: 
Whole-body MRI acquisitions are now feasible in times of less than 1 hour, usually 30-60 minutes for 
the detection and characterization of skeletal lesions.(102) In addition to the standard morphological 
sequences including T1-weighted and T2-weighted sequences, diffusion-weighted imaging (DWI) is 
now frequently included.(26,27,103) The lack of ionizing radiation, high spatial and tissue contrast 
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resolution and high sensitivity are advantages of WB-MRI such that WB-MRI is being adopted into 
clinical protocols with recent guidance on acquisition and interpretation having been published for 
metastases from prostate cancer.(100)  
There are potential disadvantages of WB-MRI including motion artefacts during the relatively long 
acquisition, limited access to busy MRI scanners in many institutions and the possibility that the 
addition of DWI, while improving sensitivity, may reduce specificity.(103) Nevertheless, several reports 
showing high diagnostic accuracy in breast and prostate cancer demonstrate comparable results to 
18F-choline, 18F-fluoride and 18F-FDG PET/CT.(104-107)  
 
Diffusion weighted and dynamic contrast enhanced MRI: 
The biophysical basis of diffusion weighted imaging is the microscopic displacement of water 
molecules due to thermal Brownian motion. In cancers the tumor environment restricts this motion 
(Fig. 5). This can be quantified by the ADC which reflects the rate of signal loss with increasing b-
weighting applied and is a measurement of the effective displacement of water molecules.(27, 108) 
Tumor ADC from b-values of less than 1000s/mm2 is a surrogate of the extracellular space; although 
cell size, cell arrangements, cell density, integrity of cell membranes, glandular structures, 
extracellular space viscosity and tortuosity will influence this, hence why reduced ADC has been 
attributed to higher cell density. The ADC typically increases with successful therapy when water 
molecules are more freely diffusible within the extracellular space as a result of cytotoxicity and 
reduced cell membrane integrity.  
There has been great interest in the use of diffusion weighted imaging to provide a quantitative 
measure of treatment response in skeletal metastases by measuring an increase in the diffusion of 
water molecules resulting from lower cellularity following successful treatment.(108, 109) Early reports 
suggest efficacy in determining early response in prostate cancer.(110, 111) However, a challenge with 
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sclerotic bone lesions is that there are fewer protons to produce a signal thus sclerotic metastases 
will return a low signal on T1 and T2-weighted MR images; they are also associated with lower 
diffusion and low ADC. Therefore a limitation is differentiating sclerosis following successful 
treatment from progressive disease,(110) akin to 18F-fluoride PET and bone scintigraphy. Despite this, 
this has not been shown to have a significant negative diagnostic effect in prostate cancer.(112) 
Dynamic contrast enhanced (DCE) MRI refers to the rapid acquisition of a time series of T1-weighted 
images before, during and after intravenous administration of gadolinium-based contrast agent. 
Gadolinium contrast agents are small hydrophilic molecules with a short circulation half-life, typically 
<1hour. These contrast agents shorten the T1-relaxation rate thus cause signal enhancement related 
to the delivery and leakage rate of contrast agent within the tissue of interest, providing a surrogate 
measure of angiogenesis. From kinetic modeling, the rate of perfusion and vascular leakage can be 
measured (transfer constant, Ktrans) and the rate of return into the vascular system (rate constant, 
kep) as well as the fractional extravascular extracellular volume (ve) and plasma volume (vp).(113) 
The presence of disseminated tumor cells in bone marrow in breast cancer patients may shift Ktrans 
and kep towards lower values.(114) Lesional Ktrans values may also differ depending on mutational 
status: higher Ktrans values are noted in EGFR mutated NSCLC bone metastases.(115) Changes in 
qualitative or quantitative parameters following therapy have been shown in animal models(116, 117) 
and patients with breast cancer bone metastases (change in T1 curve shape(118)) and other bone 
metastases (reduction in Ktrans).(119) A reduction in plasma volume (vp) in spinal metastases is a good 
prognostic indicator after radiotherapy.(120)  
 
Future directions: 
With increased availability of functional and hybrid imaging, many of the methods described above 
are accessible in the clinic. While these methods offer improved diagnostic accuracy it remains 
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unclear which method works best in each cancer type and at different stages of the management 
pathway. Comparative studies are therefore required, preferably multicenter ones that will help 
standardize protocols and analysis. It remains unclear on the best analysis method for skeletal 
metastases, i.e. should a sample of metastases be selected with the risk of not taking into account 
lesion heterogeneity, or all metastases be included in a whole body skeletal burden method. The 
clinical impact of heterogeneity of response between metastases in an individual patient also needs 
to be evaluated. As well as refining current techniques, targeting other aspects of abnormal 
metastasis or bone microenvironment biology may be fruitful with osteoclasts being an attractive 
target given their central role in most skeletal metastases and the number of treatments targeting 
osteoclast activity that are reaching the clinic.  
 
Conclusions:  
There is no doubt that functional and hybrid imaging methods including SPECT/CT, PET/CT, WB-MRI 
complemented with DWI and PET/MRI can improve the detection of skeletal metastases and early 
data suggest that earlier and more accurate treatment response is possible. Some of these methods, 
including 18F-FDG PET/CT and WB-MRI with DWI are already entering routine clinical practice but 
large-scale studies with health economics analysis is required to guide best practice and optimal 
clinical management of patients with skeletal metastases in the future. 
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Figure Legends:  
Fig. 1: A man with a new diagnosis of high-risk prostate cancer and elevated PSA. The posterior 
planar scan (a) shows a small focus of activity at L1 which is difficult to characterize. The coronal 
SPECT/CT images (b) show higher contrast resolution on SPECT (left), a typical sclerotic focus on CT 
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(middle) combined on the fused SPECT/CT image (right) with overall typical appearances of a 
metastasis. 
Fig. 2: A woman with metastatic breast cancer. 18F-fluoride PET maximum intensity projection 
image demonstrating high tracer uptake in several metastatic lesions. 
Fig 3. A woman with metastatic breast cancer. 18F-FDG PET maximum intensity projection images 
before (left) and 8 weeks (right) after commencing endocrine treatment show a metabolic response 
at all skeletal metastatic sites. 
Fig. 4: A man with biochemical recurrence of prostate cancer. A 68Ga-PSMA PET/CT scan shows a 
small metastasis in the left posterior acetabulum (arrows), invisible on the CT component of the 
study (bottom left). 
Fig. 5: T1-weighted (left), T2-weighted (centre) and diffusion-weighted inverted MIP (b800 s/mm2) 
(right) sagittal sequences demonstrating multiple bone metastases in a patient with metastatic 
breast cancer. The metastases show low signal on T1-weighted images, low to intermediate signal 
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CT – computed tomography, SPECT – single photon emission computed tomography, MDP – 
methylene diphosphonate, PET – positron emission tomography, FDG – fluorodeoxyglucose, PSMA – 
prostate-specific membrane antigen, DW-MRI – diffusion-weighted magnetic resonance imaging, 
DCE-MRI – dynamic contrast-enhanced MRI, IV – intravenous, 11C – carbon-11, 18F – fluorine-18, 
68Ga- gallium 
 
 
